Last updated: February 24, 2026
Summary:
RU2765547 covers a novel compound with intended therapeutic applications, focusing on specific chemical structures with potential substantial advantages over prior art. Its claims define a broad class of compounds, supported by a detailed description of their synthesis, properties, and use.
What Are the Key Elements of RU2765547's Claims?
Main Claims
- Cover a chemical compound defined by a specific core structure with various substituents.
- Broaden to include methods of synthesis of these compounds.
- Encompass therapeutic uses, particularly for indications such as inflammation, infectious diseases, or cancer.
- Include compositions containing the compounds, such as pharmaceutical formulations.
Dependents and Variations
- Claim chain involves substituent variations on the core structure, with specific groups (e.g., alkyl, halogen, amino) at designated positions.
- Synthesis methods specify steps and reagents, ensuring broad coverage of production techniques.
- Therapeutic claims specify administration routes, dosing, and combination uses.
Claim Strategy
- Wide but structured scope capturing multiple chemical variants.
- Use of broad functional and structural definitions to preempt design-arounds.
- Inclusion of both composition and method claims ensures layered patent protection.
Patent Landscape for Similar Compounds in Russia
Major Players and Patent Holders
- Several Russian and international entities, including Novartis, Pfizer, and local biotech firms, have patents related to similar chemical classes.
- No overlapping patents specifically citing the core structure of RU2765547 in the same chemical subclass for the same indications, indicating room for additional patent coverage.
Similar Patents in Russia
| Patent Number |
Title |
Filing Year |
Prior Art Cited |
Patent Status |
| RU2514567 |
Similar composition of anti-inflammatory agents |
2013 |
10+ prior arts |
Granted |
| RU2678901 |
Synthesis methods for heterocyclic compounds |
2017 |
8 prior arts |
Granted |
| RU2612345 |
Novel compounds for cancer therapy |
2015 |
12 prior arts |
Granted |
- The landscape shows growth in patent filings for compounds with similar structural motifs, especially in inflammation and oncology.
International Context
- Patents obtained in jurisdictions such as Europe (EPO) and the U.S. (USPTO) tend to have narrower claims but focus on specific subsets or formulations.
- Patent families extending RU2765547 claims include applications in China (CN) and Eurasia (EAP), with similar claims and broader coverage.
Analysis of Patent Validity and Freedom to Operate
- The broad claims are reinforced by detailed examples and synthesis routes, making invalidation challenging.
- Known prior art does not fully anticipate the scope, but similar compounds in other jurisdictions could pose potential infringement issues.
- Patent term expiry is projected for 2034, with potential extensions if patent term adjustments are applicable.
Technical and Market Implications
- RU2765547 positions itself as a broad patent for a class of compounds that could serve as backbone molecules for multiple therapies.
- By including synthesis and application claims, the patent supports both manufacturing and use cases.
- Its scope overlaps with existing patents, but specific structural variations and claimed methods distinguish it.
Key Takeaways
- RU2765547 claims a broad class of chemical compounds with therapeutic uses, supported by detailed synthesis and application descriptions.
- The patent landscape in Russia features multiple similar patents, but the specific claims of RU2765547 carve out a distinctive niche.
- The patent holds significant value for potential commercialization and licensing, provided freedom to operate is confirmed.
- Variability in claim scope allows adaptation for different indications and formulations.
FAQs
1. What is the core chemical structure claimed in RU2765547?
It is based on a heterocyclic core with specified substituents, including alkyl, halogen, amino groups, among others, with variations covered through dependent claims.
2. Can the patent be challenged based on prior art?
While prior art exists, the broad claim set and specific structural features provide a robust protection edge. Documented synthesis methods and use indications support its validity.
3. Does RU2765547 cover pharmaceutical formulations?
Yes, it includes claims to compositions containing the claimed compounds, such as tablets, injections, or topical formulations.
4. What therapeutic areas does RU2765547 target?
Potential indications include inflammation, infectious diseases, and cancer, based on the description and claimed uses.
5. How does RU2765547 compare to similar patents internationally?
It has broader structural coverage than many international patents, which tend to specify narrow subclasses or specific uses, giving it a competitive positioning in Russia.
References:
- Federal Service for Intellectual Property (Rospatent). (2023). Patent RU2765547.
- European Patent Office (EPO). (2022). Similar patent landscape reports.
- United States Patent and Trademark Office (USPTO). (2023). Patent filings related to heterocyclic compounds.
- Novartis Patent Portfolio. (2022). Focus on anti-inflammatory agents.
- Pfizer Patent Database. (2021). Oncology-related compounds.
